Related Experiment Video
Updated: Jan 6, 2026

Intravital Microscopy of Monocyte Homing and Tumor-Related Angiogenesis in a Murine Model of Peripheral Arterial Disease
Published on: August 26, 2017
Inhibiting Monocyte Migration Reduces Arterial Thrombosis and Facilitates Thrombolysis
Hee Jeong Jang1,2, Jiwon Kim1,2, Ha Kim1,2
1Department of Neurology (H.J.J., J.K., H.K., T.K., D.-E.K.), Dongguk University Ilsan Hospital, Goyang, Republic of Korea.
Insights
CCR2 knockout reduces platelet aggregation and thrombus formation in arterial thrombosis models. This monocyte deficiency leads to smaller, more porous, and easily lysed clots, impacting stroke and myocardial infarction research.
Area of Science:
- Cardiovascular Biology
- Hematology
- Immunology
Background:
- Monocytes are key in venous thrombosis but their role in arterial thrombosis (stroke, myocardial infarction) is unclear.
- Understanding monocyte involvement in arterial clot formation is crucial for developing new therapies.
Purpose of the Study:
- To investigate the role of CC chemokine receptor 2 (CCR2) and monocyte deficiency in arterial thrombosis.
- To determine the impact of CCR2 knockout on platelet function, coagulation, thrombus characteristics, and lysis.
Main Methods:
- Utilized FeCl3-induced carotid arterial thrombosis model in CCR2 knockout (CCR2-/-) and wild-type (WT) mice.
- Employed intravital microscopy, flow cytometry, platelet function assays, and micro-CT imaging.
- Assessed thrombus volume, porosity, fibrin cross-linking, and response to thrombolysis.
Main Results:
- CCR2-/- mice exhibited reduced platelet aggregation and fewer monocyte-platelet aggregates.
- Thrombi in CCR2-/- mice were smaller, more porous, with reduced fibrin cross-linking.
- CCR2 deficiency enhanced tissue-type plasminogen activator (tPA)-mediated thrombolysis.
Conclusions:
- CCR2 antagonism impairs platelet function and reduces Factor XIII (FXIII) levels.
- Monocyte deficiency promotes the formation of smaller, more lysable arterial thrombi.
- Targeting CCR2 may offer a therapeutic strategy for arterial thrombosis.
Background:
Monocytes contribute to the initiation and propagation of venous thrombosis. Little is known about the roles monocytes play in arterial thrombosis, the cause of stroke and myocardial infarction.
Methods:
We investigated how CCR2 (CC chemokine receptor 2) knockout (-/-)-mediated monocyte deficiency affects platelet function, blood coagulation, thrombus volume, and thrombolytic susceptibility in 666 male mice with FeCl3-mediated carotid arterial thrombosis, including 365 C57BL/6 wild type (WT) mice, 295 CCR2-/- mice, and 6 CX3CR1-GFP (CX3C chemokine receptor 1-green fluorescent protein) mice.
Results:
Intravital microscopy and flow cytometry showed that both neutrophils and monocytes were recruited to the acute arterial thrombus, as observed 30 minutes post-thrombosis. Platelet function tests demonstrated platelet aggregation to be lower in the whole blood of CCR2-/- mice (versus C57BL/6 WT mice) but not in their leukocyte-free platelet-rich plasma, suggesting this platelet dysfunction is cell-mediated. Flow cytometry experiments revealed lower numbers of monocyte-platelet aggregates in the blood of CCR2-/- mice, compared with C57BL/6 WT mice. Blood levels of FXIII (factor XIII) and monocyte levels of FXIII-A were increased after carotid thrombosis in C57BL/6 WT mice but not CCR2-/- mice. Further, in vivo micro-computed tomography-based thrombus imaging using fibrin-targeted gold nanoparticles and histology showed that CCR2-/- mice had smaller thrombi (0.112±0.002 mm3, n=22) than C57BL/6 WT mice (0.125±0.007 mm3, n=27; P<0.01), with increased porosity and reduced fibrin cross-linking. Moreover, tPA (tissue-type plasminogen activator) mediated thrombus volume reduction progressed up to ≈1 hour faster during the initial 3-hour period in CCR2-/- mice and CCR2-siRNA-treated mice, compared with C57BL/6 WT mice. In addition, clopidogrel reduced baseline thrombus volume more, but CCR2-/- better facilitated tPA-mediated thrombolysis.
Conclusions:
CCR2 antagonism decreases platelet aggregation and reduces FXIII levels in blood and monocytes, thus driving arterial thrombosis towards the generation of a relatively small, porous, more lysable clot.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Clot Retraction and Fibrinolysis
Venous Thrombosis III: Interprofessional Care
Atherosclerosis III: Management

